抗血栓治疗患者接受水刀消融术:安全性、术后出血率与临床结局评估
基于WATER前瞻性试验(NCT02505919)的116例男性,按围术期是否使用抗血栓药物分为两组,比较水刀消融术后出血结局。抗血栓组41例与未用抗血栓组75例在术后血红蛋白变化、Clavien-Dindo 1级和2级并发症及需血制品方面均无显著差异,两组均无新发勃起功能障碍。
要点
- 抗血栓组与未用抗血栓组术后血红蛋白下降分别为1.8±1.5 g/dL与1.8±1.7 g/dL,组间无显著差异(P=0.896)。
- 抗血栓组4例(9.8%)与未用抗血栓组4例(5.3%)发生Clavien-Dindo 1级并发症,无显著差异(P=0.451)。
- 抗血栓组1例(2.4%)需血制品,未用抗血栓组无,无显著差异(P=0.353)。
核心结论
- 水刀消融术在围术期使用抗血栓治疗的良性前列腺增生男性中,术后出血结局及其他不良事件与未用抗血栓药物者相当。
研究设计与样本
- WATER前瞻性试验(NCT02505919)的116例接受水刀消融术的男性,按围术期抗血栓状态分为抗血栓组41例与未用抗血栓组75例。
- 抗血栓药物的停用与恢复时机由术者决定,术中止血采用非电凝球囊填塞或电凝。
主要发现
- 术后血红蛋白较基线下降:抗血栓组1.8±1.5 g/dL vs 未用抗血栓组1.8±1.7 g/dL,组间无显著差异(P=0.896)。
- 术后3个月内Clavien-Dindo 1级并发症:抗血栓组4例(9.8%)vs 未用抗血栓组4例(5.3%),无显著差异(P=0.451)。
- Clavien-Dindo 2级并发症:抗血栓组8例(19.5%)vs 未用抗抗血栓组11例(14.7%),无显著差异(P=0.601),两组均无出血相关事件。
- 需血制品:抗血栓组1例(2.4%)vs 未用抗血栓组0例,无显著差异(P=0.353)。
- 两组均无新发勃起功能障碍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the impact of perioperative antithrombotic use on the bleeding outcomes following Aquablation. METHODS: One hundred sixteen men with who underwent Aquablation as part of the WATER prospective trial (NCT02505919) were assigned to 2 groups based on perioperative antithrombotic status. Antithrombotic cessation and restart timing were based on the surgeon's discretion. Methods of achieving intraoperative hemostasis consisted of no-cautery balloon tamponade or cautery. Primary endpoints included immediate postoperative hematuria rates and changes in hemoglobin. Secondary endpoints included 90-day bleeding complications and nonbleeding postoperative adverse events. RESULTS: Forty-one men took antithrombotic medications in the perioperative period while 75 men had no antithrombotic medication. Preoperative hemoglobin levels were comparable between both groups. Postoperative hemoglobin change from baseline (drop of 1.8 ± 1.5 g/dL among the antithrombotic group vs 1.8 ± 1.7 g/dL among the antithrombotic-naïve group) did not differ between both groups (P = .896). In total, 4 (9.8%) men in the antithrombotic group and 4 (5.3%) patients in the antithrombotic-naïve group experienced a Clavien-Dindo grade 1 complication (P = .451) in the 3-month postoperative period. Eight (19.5%) patients in the antithrombotic group and 11 (14.7%) patients in the antithrombotic-naïve group experienced a Clavien-Dindo grade 2 complication (P = .601), none of which is associated with bleeding in both groups. No men in either group demonstrated de novo erectile dysfunction. One patient (2.4%) in the antithrombotic group and none in the antithrombotic-naïve group required blood products (P = .353). CONCLUSION: Aquablation demonstrates comparable postoperative bleeding outcomes and other adverse effects for men with benign prostatic hypertrophy who are on antithrombotic therapy.
引用
- Sadri I, Chakraborty A, Nguyen DD, et al. Aquablation in Patients on Antithrombotics: Assessment of Safety, Postoperative Bleeding Rates and Clinical Outcomes. Urology. 2023. PMID: 37574143. doi:10.1016/j.urology.2023.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。